Imunização contra influenza no Brasil: racionalidade e desafios by Cunha, Sérgio Souza da et al.
  	
 

 ! 
Influenza vaccination in Brazil: rationale and
caveats
Imunização contra Influenza no Brasil:
racionalidade e desafios
Sérgio Souza da Cunhaa, Luiz Antonio B Camachob, Andréia Costa Santosa and Inês
Douradoa
aInstituto de Saúde Coletiva. Universidade Federal da Bahia.Salvador, BA, Brasil. bEscola Nacional de
Saúde Pública. Fundação Oswaldo Cruz (Fiocruz). Rio de Janeiro, RJ, Brasil
Correspondence to:
Luiz A. B. Camacho
Escola Nacional de Saúde Pública - Fiocruz
R. Leopoldo Bulhões, 1480 Sl. 820 Manguinhos
21041-210 Rio de Janeiro, RJ, Brasil
E-mail: luiz.camacho@ensp.fiocruz.br
Received on 24/9/2003. Approved on 8/7/2004.
Keywords
Influenza. Influenza vaccine. Program
evaluation. Immunization programs.
Descritores
Influenza. Vacina contra influenza.
Avaliação de programas. Programas
de imunização.
INTRODUCTION
Vaccination is generally considered a very impor-
tant tool for disease control, and immunization pro-
grams are among the most successful interventions in
public health. The package of vaccines recommended
by the Expanded Program of Immunization (EPI) is
well established as the basic set of immunization ac-
tivities. As the growing number of licensed vaccines
expands the available arsenal, policymakers face the
Abstract
Mass vaccination campaigns against influenza in the elderly have been conducted in
Brazil since 1999. A search of the literature on influenza in Brazil indicated that data
on disease burden are still scarce and inaccurate. Published data seem to indicate that
vaccination has produced some impact in the southern and southeastern regions but
not in other regions of Brazil. A discussion of the technical and scientific rationale for
mass immunization against influenza is presented and it is argued that the current
strategy has not taken into account potential differences in disease occurrence in
different areas. It is suggested some epidemiological surveillance actions needed to
address major concerns regarding mass influenza vaccination and its impact in Brazil.
Resumo
Campanhas de vacinação contra influenza na população idosa têm sido conduzidas
no Brasil desde 1999. De acordo com levantamento da literatura realizada sobre
influenza no Brasil, concluiu-se que dados sobre carga de doença são ainda escassos
e imprecisos. Essas informações parecem indicar que a vacinação tem produzido
algum impacto nas regiões Sul e Sudeste do País, mas não em outras regiões. Foram
discutidas racionalidade técnica e científica para a imunização contra influenza, e
argumentou-se que a atual estratégia de vacinação em todo o território nacional não
levou em conta possíveis diferenças na ocorrência da doença causada por influenza
entre as regiões do País. Foram sugeridas algumas atividades relacionadas à
vigilância epidemiológica de influenza que se julgou necessárias para responder
importantes questões referentes à vacinação e seu impacto no Brasil.
decision on which vaccine should be included in im-
munization programs. Several aspects should be con-
sidered by program managers such as disease burden,
vaccine protection, and economic aspects.7 Although
support for the implementation of public interventions
is not always based on consensus, policymakers should
base their decisions on technical grounds.51
It is recognized that the importance of influenza
infection in tropical areas is poorly understood, and
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research addressing this topic should be stimulated.39
However, it is not clear whether immunization as a
result of vaccination for controlling annual epidem-
ics plays a role in the preparedness against pandem-
ics. There is no evidence so far that influenza vacci-
nation led to a reduction in disease burden in tropi-
cal areas of Brazil, such as the Northern and North-
eastern regions. In this scenario, immunization in
tropical areas should be preceded by virus surveil-
lance, assessment of disease burden and economic
impact of annual influenza epidemics, as recom-
mended by the 56th World Health Assembly on plan-
ning for preparedness for influenza pandemics and
annual epidemics in the item regarding areas where
there is no vaccination policy.52
The aim of the study is to present an analysis of the
implementation of annual mass immunization cam-
paign against influenza for people aged 60 years and
older in Brazil focusing on its technical and scien-
tific rationale. However, it is acknowledged the role
of political will and government commitment as im-
portant elements in the decision making process. It is
also acknowledged that progress has been made in
influenza surveillance and control since public-
funded mass immunization has started in Brazil. Still,
the debate on principles for introducing new vac-
cines is thought to be valuable in the future.
ISSUES CONCERNING THE IMPLEMENTATION
OF NEW VACCINES – THE CASE OF
INFLUENZA
Some important technical issues guiding the deci-
sion making process for introducing new vaccines
are: magnitude and distribution of the public health
problem posed by the disease; availability of safe
and efficacious vaccines; and social and economic
implications of the intervention.7
DISEASE BURDEN: WHAT IS TO BE
PREVENTED?
The clinical presentation of influenza is typically
a syndrome comprising fever, myalgia, headache, se-
vere malaise, non-productive cough, sore throat, and
rhinorrhea, called “influenza-like illness”.5 In some
individuals, influenza can cause severe disease, which
often involves bacterial complications such as pneu-
monia, or exacerbation of underlying conditions such
as pulmonary or cardiac disease.5 Elderly population
is a high risk group for severe complications of influ-
enza, which lead to hospitalizations and deaths.20 The
association of influenza infection and severe illness
in this population is inferred from the link between
seasonal increase in morbidity and mortality rates of
respiratory disease and detection of influenza virus
in the absence of other viruses.19 This evidence sup-
ports vaccination against influenza targeting elderly
population and applied before seasonal peaks.
The major benefit expected from vaccination in
elderly population is a reduction of severe cases. Mild
disease, absenteeism and loss of productivity are usu-
ally not considered major aims for vaccinating this
population. It is important to note that influenza in-
fection is not the only risk factor related to seasonal
outbreaks of severe respiratory disease in elderly
population.14,18,37,38 Furthermore, influenza infection
does not always indicate detectable increase in the
number of clinical cases.6
Influenza vaccination will only reduce the inci-
dence of respiratory disease related to influenza in-
fection. This component of respiratory morbidity cor-
responds to the epidemiological measure of poten-
tial impact known as “population attributable frac-
tion,” which can be interpreted as the proportion of
the incidence of a disease in a population attributed
to a specified factor.25 This measure is a function of
two factors: (1) magnitude of the incidence of influ-
enza infection; and (2) magnitude of the association
between influenza infection and morbidity and mor-
tality due to respiratory diseases. This association is
chiefly measured by the excess morbidity and mor-
tality during seasonal periods and the concomitant
detection of influenza virus, and not just by the inci-
dence of respiratory disease.19 A high incidence of
pneumonia in elderly population does not necessar-
ily mean that influenza virus plays an important role
in the disease burden related to these cases.
VACCINE PROTECTION
To address the issue of vaccine protection the con-
cepts of efficacy and effectiveness must be clarified.
Vaccine efficacy is the percent reduction in the inci-
dence of a disease among vaccinated compared to
unvaccinated individuals under controlled condi-
tions, and often based on laboratory confirmed
cases.8,34 These study results can not be taken straight-
forwardly as indicating the effect of influenza vacci-
nation under routine conditions, i. e., in health care
units or mass immunization campaigns. Sub-optimal
conditions prevail in routine or campaign immuni-
zation settings and vaccination in such a context is
likely to have a lesser impact than that observed in
efficacy studies. It should be noted that most studies
on influenza vaccine were conducted among healthy
young adults and the estimates of vaccine efficacy
were for influenza-like disease,34 not for severe cases.
Efficacy estimates have ranged from 70% to 90% in
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laboratory confirmed cases. At least three clinical tri-
als conducted among elderly people found vaccine
efficacy between 60% and 67% in laboratory con-
firmed influenza-like illness,15,21,45 not in severe cases
leading to hospitalizations or death.
Differently, vaccine effectiveness is the percent re-
duction in the incidence of a disease among vacci-
nated compared to unvaccinated individuals under
routine conditions, and may include cases regardless
of laboratory confirmation, that is, non-influenza
cases.8,34 Most studies estimating vaccine effective-
ness among elderly people were observational. The
estimate of vaccine effectiveness depends greatly on
the outcome of interest. For example, in the meta-
analysis carried out by Gross et al,22 vaccine protec-
tion ranged from 50% for pneumonia to 67% for death.
A study conducted in United Kingdom among indi-
viduals aged 64 years or more showed a 21% vaccine
effectiveness against hospitalizations for acute res-
piratory disease (with no reduction in hospital ad-
missions outside influenza seasons).29 In a retrospec-
tive cohort study conducted in the Netherlands, no
effect of vaccination was found on the contact rate of
general practice during a mild epidemic period, and
during an influenza epidemic the workload was re-
duced only in patients with cardiovascular or dia-
betic disease.49 Result generalization depends on the
comparability of aspects such as vaccine storage and
delivery, routine case definition, coverage rate, and
contribution of influenza to disease burden. Further-
more, vaccine effectiveness also depends on antigenic
match between the vaccine and circulating strains.
HEALTH ECONOMIC EVALUATIONS
In all societies, there are usually several health prob-
lems contending for limited resources, which make
policymakers to set priorities in fund allocation. Ide-
ally, the decision making process should use avail-
able information from health economic evaluation
(HEE).2,12,27 HEE assesses the existing balance between
resources and health outcomes, assisting in compar-
ing and choosing interventions based on their ben-
efits and available funds. There is a wide range of
different types of evaluations, which can be carried
out even before the implementation of a vaccination
program.2 The outcomes can be appraised to repre-
sent preferences and priorities according to different
viewpoints: society, government, and individual. In
Brazil, HEE can generate crucial information, given
the diversity in performance of health services, eco-
nomic and epidemiological profiles, which imply
different costs and priorities across the country.
Many HEE on influenza vaccination in elderly
people concluded that vaccination was a cost-saving
measure.10,16,17,26,33,35,36,44 However, these results should
be treated with great caution as they are very sensi-
tive to differences in medical care and vaccination
costs, and to the proportion of cases of severe respira-
tory disease related to influenza in each context. For
example, if influenza occurs throughout the year with-
out a seasonal pattern (as it seems to be in some Bra-
zilian states), and is not importantly associated with
hospitalization among elderly people, then vaccina-
tion against influenza may not be a cost-saving meas-
ure from a societal point of view.17 As another exam-
ple, Allsup et al1 conducted a randomized trial aimed
to assess the cost-benefit of vaccination and con-
cluded that vaccination among healthy people aged
65-74 years has not led to lower costs in primary care
units in England and Wales.1
INFLUENZA VACCINATION IN BRAZIL
Mass immunization against influenza in Brazil
started in 1999, at first targeting 11 million individu-
als aged 65 years or more. In 2000, the age limit was
shifted to 60 years old. National immunization cam-
paigns achieved a vaccination coverage rate ranging
from 71.8% to 87.3%.48 One of the major conditions
that seemed to have favored the implementation of
vaccination against influenza in Brazil was the suc-
cess of the Brazilian National Immunization Program
(PNI) of infant recommended vaccination. Only a
mature immunization program could face the chal-
lenges posed by influenza vaccine: the need for yearly
immunization in mass campaigns, and for achieving
high coverage rates in a subset of the adult popula-
tion using a vaccine that cannot be stockpiled be-
cause of annual changes in their composition.
STUDIES ON INFLUENZA IN BRAZIL
A literature search was conducted in data bases
LILACs (Latin-American and Caribbean Health) and
PUBMED between May-June 2003 (and reviewed in
August 2004). The articles were short-listed to in-
clude only those with data on adult population ob-
tained from the 1980s and onwards. There may be
other studies but if so they were not published and
thus were not available to be reviewed.
Several serological surveys were conducted in adult
populations, mostly based on specific sub-popula-
tions such as students28 and patients attending health
services.9,13,24,32,46 It is worth noting that only one was
a population-based study,50 and all of these studies,
except two,9,46 were conducted in the Southern parts
of the country. More recently, Paiva et al41 showed
the circulating virus strain without estimating vac-
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cine efficacy. As most study populations came from
specific sub-groups, generalization for a community
at large had many pitfalls. These studies were very
helpful in determining the circulating virus strains
but did not contribute to assess either disease burden
or the clinical attack rate of influenza.
There were some studies aimed to assess the impact
of influenza vaccination. Paiva et al42 described an
outbreak of acute respiratory disease in a city of the
Southeastern state of São Paulo in 1999, in which
most cases were among individuals younger than 14
years old, but there is no reference of rates by age
group. In that study population, the 1999 influenza
campaign (before the outbreak) achieved a 72.4%
coverage rate among those aged 65 years or more,
and no case was observed in this age group. The latter
suggested to the authors that vaccination elicited
high protection against respiratory disease. However,
vaccine effectiveness was not estimated.
Gutierrez et al23 described a retrospective cohort
study conducted in a reference service in the city of
São Paulo. This study aimed to assess whether the
occurrence of respiratory disease in elderly popula-
tion was different between those vaccinated and those
unvaccinated against influenza in the 1999 campaign.
There were no apparent differences related to the pro-
portions of individuals who reported hospitalization,
hospitalization for respiratory diseases, and antibiot-
ics use (a proxy for bacterial infection and pneumo-
nia). This finding could be due to lack of study power,
but there was no description of such an estimate or
sample size calculation. However, it was observed a
statistically significant difference related to the
number of episodes of influenza-like illness: vacci-
nated subjects had a lower mean number of episodes
(1.5) than those unvaccinated (2.25). As these results
were expressed in terms of mean values, they cannot
be translated into vaccine effectiveness (percent re-
duction in incidence).
Brondi et al3 reported a decrease in hospital admis-
sion rates observed after vaccination in the Southern
and Southeastern regions of Brazil, but not in other
regions. According to this study, the number of
hospitalizations from pneumonia and chronic pulmo-
nary obstructive disease in individuals in the vacci-
nated age group decreased in these regions in com-
parison to the period 1995-1998. Silvestre48 also
showed a 19.1% reduction in hospitalizations for pneu-
monia between June-August of the period 1999-2001
in comparison to the same period a year before the
launch of the mass vaccination campaign. This reduc-
tion did not occur in age groups outside the target
population. Unfortunately, these results were repre-
sentative of the entire country and whether this reduc-
tion occurred in tropical areas was not showed, and the
southern and southeastern regions were certainly
overrepresented. Therefore, it is not possible to say this
result can be generalized for the entire country.
Mixeu et al31 reported a randomized trial among
healthy adults members of a Brazilian airline com-
pany and observed a 33% vaccine effectiveness for
episodes of any severe flu-like illness and reduction
in absenteeism.31 However, these results can not be
applied to vaccination targeting elderly people.
Economic assessments of mass immunization
against influenza are scarce. Burckel et al4 reported
the only health economic evaluation carried out but
it included only healthy workers and its results could
not be applied to elderly people.
CAVEATS ON THE DECISION MAKING
PROCESS OF IMPLEMENTING MASS
IMMUNIZATION OF THE ELDERLY AGAINST
INFLUENZA IN BRAZIL
Reliable data are often unavailable to guide the
decision making process in specific contexts, and
the decision may be based on expertise judgment
and literature review. However, caution should be
exercised in using evidence from published results
on influenza vaccine to analyze the Brazilian con-
text. First, virus surveillance conducted in Brazil has
demonstrated that influenza virus circulates in the
country, and has shown the viral strains prevailing in
specific settings.40 However, this virus surveillance
has neither contributed substantially to assess dis-
ease burden nor to assess the clinical attack rate of
influenza. Second, most studies on influenza vaccine
were conducted in the Northern Hemisphere, in coun-
tries with temperate climate where influenza peaks of
incidence occur during the winter (influenza season).
In those studies, influenza is recognized as an impor-
tant cause of severe disease among elderly, leading
to excess morbidity and mortality. At most, these re-
sults could be cautiously generalized to South and
Southeast regions of Brazil, which have temperate
climates. In Brazil, a large proportion of the popula-
tion live in tropical areas, mainly in the Northeast
and North regions, and there are around 4,880,000
inhabitants aged 60 years or older.30
In tropical and subtropical areas, circulation of in-
fluenza viruses occur throughout the year.53 Indeed, a
seasonal pattern is less pronounced in tropical areas,
such as the North and Northeast Brazil, and the ab-
sence of seasonal peaks of respiratory diseases in these
regions raises other questions. First, how can it be
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assumed that influenza-related disease burden is im-
portant in such areas since there is no recognizable
excess of morbidity and mortality? One could argue
that the available data are on hospitalizations and
there may still be severe cases unreported. However,
these data are not available either. Second, seasonal
peaks of influenza-related diseases, which occur in
temperate areas, indicate a temporal concentration of
cases, and provide the opportunity to maximize vac-
cine effectiveness. In the northern regions of Brazil,
seasonal peaks may not be apparent or may occur in
the rainy season, which does not coincide with the
winter in Southern regions. Mass immunization cam-
paigns have been conducted nationwide during the
weeks preceding the influenza season in the South
and Southeast, which is not the optimum period of
the year for immunization in the Northern and North-
eastern regions. But even if the timing for implement-
ing vaccination in such regions is “adjusted”, there
is still the case of no temporal concentration of cases,
and it is reasonable to anticipate that vaccine impact
on reducing disease burden will be much less than
expected.17 In fact, Brondi et al3 have not observed
an impact in the Northern regions of Brazil.
Support for the implementation of public interven-
tions is not always based on consensus. As for influ-
enza, the recent debate on the decision of Ontario
government (Canada) to expand influenza vaccina-
tion in 200011,47 revealed the different views of manu-
facturers representatives and scholars and worked as
a good example of lack of consensus on how to im-
plement such vaccination. On one hand, it was ar-
gued that there was already convincing evidence on
the vaccine efficacy and its cost-effectiveness, and
on the importance of being prepared for an influenza
pandemic.47 On the other hand, it was argued that
there were neither predictions on the impact of such
vaccination nor estimates of disease burden related
to influenza, nor studies aimed to assess whether it
was the best way to allocate resources.11
In conclusion, it is agreed that virus surveillance is
important as the rationale for surveillance of a world-
wide infection with potential for pandemics are long
well recognized.19,39,43 But one should recast the ques-
tion: if no reduction in disease burden is observed in
all Brazilian regions, is the current annual vaccina-
tion nationwide justifiable? Policymakers often have
to make decisions despite the uncertainty of the ben-
efits of public interventions.51 It is worth reminding
that in the 1990’s vaccines against hepatitis B and
rubella were introduced in public health services in
different periods in Brazilian states based on regional
epidemiological and programmatic data. With the
same rationale, it may be justifiable to reexamine
mass immunization against influenza in the northern
parts of the country.
THE ROLE OF INFLUENZA
EPIDEMIOLOGICAL SURVEILLANCE
Given such considerations, it is envisaged three
major activities of the influenza surveillance system
to address questions to guide the decision making
process in health policy.
First, it is necessary to better determine the burden
of the influenza-related diseases.39 This task implies
not only identifying prevailing viral strains and as-
certaining antigenic vaccine match but also estimat-
ing the contribution of influenza to morbidity and
mortality in different regions.
Second, it is necessary to demonstrate whether influ-
enza vaccination through immunization campaigns
has been able to reduce disease burden and, if so, where
this was achieved. Establishing the areas where vacci-
nation is effective is particularly important where cli-
mate conditions and epidemiologic profile of respira-
tory diseases among elderly people differ from those
of temperate settings. This is a challenging task given
that influenza may have seasonal distribution, the pro-
portion of severe respiratory disease related to influ-
enza varies with age, and large-scale vaccinations were
already implemented. All these factors imply meth-
odological difficulties such as:
(1) the simple comparison of hospitalization rates
before and after vaccination in short time-series
may be limited to show vaccine impact, given
natural and temporal variations in disease
occurrence. Preliminary evidence of the impact
of immunization against influenza on elderly
population needs further analysis since available
data on hospitalizations may be unreliable as the
records are generated for billing purposes. More-
over, hospital admission is taken as a proxy of
disease severity but regional differences in access
to health care and in care seeking behavior may
hamper comparability across regions;
(2) as occurrence and severity of influenza-related
diseases varies with age, hospitalization rates among
those aged below 60 years (outside vaccination target
population) cannot be used to indicate disease
occurrence in the target population, neither for the
rates among unvaccinated individuals nor for the
temporal variations;
(3) vaccination coverage rate and contribution of
influenza to hospitalization rates vary in different
regions, implying that any assessment should be
undertaken and reported separately for each
geographical area rather than for the whole country,
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given that the South and Southeast regions are over
represented.
Third, economic evaluations are essential to rank
priorities for immunization across states, consider-
ing vaccine high costs and differences in the eco-
nomic burden from other compelling diseases and
their control programs.
These actions require the partnership of research
centers to be better managed. The result of time and
resources invested in such actions are invaluable con-
sidering that the effort to start and maintain addi-
tional vaccination activities are substantial, and once
started, it is very difficult to justify its discontinua-
tion to the community.
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